---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-090232"
form_type: "8-K"
ticker: "ATNM"
cik: "0001388320"
company_name: "Actinium Pharmaceuticals, Inc."
filed_at: "2026-08-14T21:00:38+00:00"
generated_at: "2026-08-14T21:02:12.974300+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Actinium gets NYSE plan acceptance through Nov 2027; adds Actimab-A patents and manufacturing

## Summary
- NYSE Regulation accepted compliance plan; listing extended through Nov 27, 2027, maximum period under Section 1009.
- Three US patents issued for Actimab-A: US 12,491,274 (sarcoma), US 12,539,340 (solid tumors), US 12,410,249 (low blast AML).
- Canadian applications for venetoclax combo and CLAG-M combo advanced to pre-grant/allowed status.
- Added second manufacturer under IND; will supply NCI CRADA and company studies with milestones from H2 2026.
- Company remains non-compliant with Sections 1003(a)(ii) and (iii); delisting risk if plan not met by Nov 2027.

## SEC filing metadata
- accession: 0001213900-26-090232
- form_type: 8-K
- ticker: ATNM
- cik: 0001388320
- company_name: Actinium Pharmaceuticals, Inc.
- filed_at: 2026-08-14T21:00:38+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1388320/000121390026090232/0001213900-26-090232-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1388320/000121390026090232/ea0301890-8k_actinium.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-090232
- JSON: https://secwatch.observer/filing/0001213900-26-090232.json
- Plain text: https://secwatch.observer/filing/0001213900-26-090232.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.